NeuroMetrix announced today that Senior Vice President and Chief Commercial Officer Frank McGillin will present on Quell® Wearable Pain Relief Technology™ during the 16th Annual Diabetes Technology Meeting, November 10-12, in Bethesda, Maryland.
NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that Senior Vice President and Chief Commercial Officer Frank McGillin will present on Quell® Wearable Pain Relief Technology™ during the 16th Annual Diabetes Technology Meeting, November 10-12, in Bethesda, Maryland.
About half of people with diabetes have chronic pain. In addition to the
direct burden of pain symptoms, many of these individuals also report
that their pain impacts sleep quality, activity level, and mood, all of
which reduce quality of life and can exacerbate diabetes. Moreover,
clinical studies have shown that chronic pain can limit diabetes
self-care behaviors, which are essential for minimizing diabetes-related
“We are excited to demonstrate Quell pain relief technology to the
researchers who are leading the effort to discover innovative ways to
address the challenges faced by people with diabetes,” said McGillin.
“Since one of the focus areas of this year’s meeting is big data, we are
particularly pleased to share early insights from the over 2,000,000
hours of user data captured in the Quell Health Cloud.”
About the Diabetes Technology Society Annual Meeting
The Annual Meeting is an opportunity for leading scientists in the field
of diabetes research to learn about the latest technological advances
for people with diabetes. Last year’s meeting in Bethesda, Maryland
brought together over 450 clinicians and scientists from 24 countries to
focus on applying science and technology to fight diabetes. Visit www.diabetestechnology.org
for more information.
Quell is designed for millions of people suffering from chronic pain.
The advanced wearable device is lightweight and can be worn during the
day while active, and at night while sleeping. It has been cleared by
the FDA for treatment of chronic pain without a prescription. In a
recent study, 81% of Quell users reported an improvement in their
chronic pain. Quell users can start, stop, and adjust therapy discreetly
via the optional Quell Relief app. Quell also offers advanced sleep
tracking that provides feedback on eight dimensions of sleep including
sleep duration, quality, body position, time out of bed, and repetitive
leg movements throughout the night. Quell was the winner of the
2016 SXSW (South by Southwest) Innovation Award for Best Wearable
Technology. Quell is available at select healthcare professionals and
retailers. Visit QuellRelief.com
for more information.
NeuroMetrix is a commercial stage, innovation driven healthcare company
combining bioelectrical and digital medicine to address chronic health
conditions including chronic pain, sleep disorders, and diabetes. The
company’s lead product is Quell, an over-the-counter wearable
therapeutic device for chronic pain. Quell is integrated into a digital
health platform that helps patients optimize their therapy and decrease
the impact of chronic pain on their quality of life. The company also
markets DPNCheck®, a rapid point-of-care test for diabetic
neuropathy, which is the most common long-term complication of Type 2
diabetes. The company maintains an active research effort and has
several pipeline programs, including a therapeutic device for restless
leg syndrome. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit www.NeuroMetrix.com.